ZA200906374B - C5 antigens and uses thereof - Google Patents
C5 antigens and uses thereofInfo
- Publication number
- ZA200906374B ZA200906374B ZA200906374A ZA200906374A ZA200906374B ZA 200906374 B ZA200906374 B ZA 200906374B ZA 200906374 A ZA200906374 A ZA 200906374A ZA 200906374 A ZA200906374 A ZA 200906374A ZA 200906374 B ZA200906374 B ZA 200906374B
- Authority
- ZA
- South Africa
- Prior art keywords
- antigens
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89640807P | 2007-03-22 | 2007-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200906374B true ZA200906374B (en) | 2010-05-26 |
Family
ID=39672693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200906374A ZA200906374B (en) | 2007-03-22 | 2009-09-14 | C5 antigens and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US20100166748A1 (fr) |
EP (1) | EP2129681A2 (fr) |
JP (1) | JP2010521194A (fr) |
KR (1) | KR20100015773A (fr) |
CN (1) | CN101679486A (fr) |
AU (1) | AU2008228247A1 (fr) |
BR (1) | BRPI0809105A2 (fr) |
CA (1) | CA2680760A1 (fr) |
CL (1) | CL2008000803A1 (fr) |
EA (1) | EA200901211A1 (fr) |
IL (1) | IL201020A0 (fr) |
MA (1) | MA31351B1 (fr) |
MX (1) | MX2009010181A (fr) |
TN (1) | TN2009000381A1 (fr) |
TW (1) | TW200848076A (fr) |
WO (1) | WO2008113834A2 (fr) |
ZA (1) | ZA200906374B (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US8703136B2 (en) | 2006-10-10 | 2014-04-22 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
US20090176654A1 (en) * | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
RU2012102021A (ru) * | 2009-06-23 | 2013-07-27 | Алексион Фармасьютикалз, Инк. | Биспецифические антитела, которые связываются с белками комплемента |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
ES2606134T3 (es) | 2011-07-29 | 2017-03-22 | Andritz S.A.S. | Centrifugador y miembro de orificio de descarga de centrifugador para reducción de potencia |
EP2583957A1 (fr) | 2011-10-18 | 2013-04-24 | LANXESS Deutschland GmbH | Butène linéaire à partir d'isobutanol |
WO2013126006A1 (fr) * | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides se fixant au composant c5 du complément humain |
US10010513B2 (en) * | 2012-05-25 | 2018-07-03 | Novartis Ag | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
EP2975055A4 (fr) * | 2013-01-31 | 2016-11-02 | Univ Seoul Nat R & Db Found | Anticorps anti-c5 et méthode de prévention et de traitement de maladies liées au complément |
SI2970974T1 (sl) | 2013-03-14 | 2017-12-29 | Alnylam Pharmaceuticals, Inc. | Komplementarna komponenta C5 sestavkov IRNA in postopki njene uporabe |
EP4223317A3 (fr) | 2014-06-12 | 2023-09-27 | RA Pharmaceuticals, Inc. | Modulation de l'activité du complément |
WO2016040589A1 (fr) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Agents polynucléotidiques ciblant le composant du complément c5 et leurs méthodes d'utilisation |
WO2016081314A1 (fr) | 2014-11-17 | 2016-05-26 | Alexion Pharmaceuticals, Inc. | Stratégie d'évaluation et de gestion des risques impliquant des suivis de patients quant à un inhibiteur du complément |
LT3233921T (lt) | 2014-12-19 | 2021-12-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antikūnai ir panaudojimo būdai |
EP3988110A1 (fr) | 2015-01-28 | 2022-04-27 | RA Pharmaceuticals, Inc. | Modulateurs d'activité complémentaire |
MX2018007352A (es) | 2015-12-16 | 2019-05-16 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
TWI747936B (zh) * | 2015-12-18 | 2021-12-01 | 日商中外製藥股份有限公司 | 抗c5抗體及使用方法 |
US20190225678A1 (en) * | 2016-06-07 | 2019-07-25 | Novartis Ag | Anti-c5 antibody for treating patients with complement c5 polymorphism |
UA126561C2 (uk) * | 2016-06-17 | 2022-11-02 | Чугаі Сейяку Кабусікі Кайся | Застосування антитіла проти с5 |
JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Il−8関連疾患の治療用又は予防用組成物 |
US20190328854A1 (en) * | 2016-08-29 | 2019-10-31 | The Cleveland Clinic Foundation | C5 immunization for autologous anti-c5 antibody production |
BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
IL269122B1 (en) * | 2017-03-06 | 2024-03-01 | Univ Pennsylvania | Antibodies against C5 and their uses |
GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
PL3612208T3 (pl) | 2017-04-21 | 2023-07-24 | Volution Immuno Pharmaceuticals Sa | Coversin do leczenia autoimmunologicznych chorób pęcherzowych |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US6673346B1 (en) * | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
WO2003078457A1 (fr) * | 2002-03-19 | 2003-09-25 | Cincinnati Children's Hospital Medical Center | Muteines d'anaphylatoxine c5a, molecules d'acides nucleiques codant pour ces muteines et utilisations pharmaceutiques des muteines d'anaphylatoxine c5a |
DK2860251T3 (en) * | 2004-02-12 | 2018-06-06 | Archemix Llc | APTAPMER PHARMACEUTICALS USEFUL IN TREATMENT OF COMPLEMENT-RELATED DISEASES |
KR20170002684A (ko) * | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
-
2008
- 2008-03-19 CA CA002680760A patent/CA2680760A1/fr not_active Abandoned
- 2008-03-19 KR KR1020097021990A patent/KR20100015773A/ko not_active Application Discontinuation
- 2008-03-19 US US12/532,261 patent/US20100166748A1/en not_active Abandoned
- 2008-03-19 CN CN200880016777A patent/CN101679486A/zh active Pending
- 2008-03-19 JP JP2010500226A patent/JP2010521194A/ja active Pending
- 2008-03-19 WO PCT/EP2008/053321 patent/WO2008113834A2/fr active Application Filing
- 2008-03-19 BR BRPI0809105A patent/BRPI0809105A2/pt not_active Application Discontinuation
- 2008-03-19 EP EP08718042A patent/EP2129681A2/fr not_active Withdrawn
- 2008-03-19 AU AU2008228247A patent/AU2008228247A1/en not_active Abandoned
- 2008-03-19 EA EA200901211A patent/EA200901211A1/ru unknown
- 2008-03-19 MX MX2009010181A patent/MX2009010181A/es unknown
- 2008-03-20 CL CL200800803A patent/CL2008000803A1/es unknown
- 2008-03-21 TW TW097110201A patent/TW200848076A/zh unknown
-
2009
- 2009-09-14 ZA ZA200906374A patent/ZA200906374B/xx unknown
- 2009-09-17 IL IL201020A patent/IL201020A0/en unknown
- 2009-09-18 TN TNP2009000381A patent/TN2009000381A1/fr unknown
- 2009-09-24 MA MA32228A patent/MA31351B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2129681A2 (fr) | 2009-12-09 |
IL201020A0 (en) | 2010-05-17 |
TW200848076A (en) | 2008-12-16 |
MA31351B1 (fr) | 2010-05-03 |
WO2008113834A3 (fr) | 2009-03-05 |
EA200901211A1 (ru) | 2010-04-30 |
MX2009010181A (es) | 2009-12-04 |
JP2010521194A (ja) | 2010-06-24 |
KR20100015773A (ko) | 2010-02-12 |
TN2009000381A1 (en) | 2010-12-31 |
US20100166748A1 (en) | 2010-07-01 |
CN101679486A (zh) | 2010-03-24 |
CA2680760A1 (fr) | 2008-09-25 |
WO2008113834A2 (fr) | 2008-09-25 |
AU2008228247A1 (en) | 2008-09-25 |
BRPI0809105A2 (pt) | 2019-09-10 |
CL2008000803A1 (es) | 2008-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200906374B (en) | C5 antigens and uses thereof | |
LT2436696T (lt) | Anti-beta-amiloido antikūnas ir jo panaudojimas | |
HK1142341A1 (en) | Anti-hepcidin antibodies and uses thereof | |
IL200012A0 (en) | Anti-robo4 antibodies and uses therefor | |
EP2236604A4 (fr) | Anticorps anti-nr10 et son utilisation | |
IL209309A0 (en) | Anti-fn14 antibodies and uses thereof | |
HK1199041A1 (en) | Sp35 antibodies and uses thereof sp35 | |
IL216731A (en) | And antibodies against p95 – her2 and their uses | |
HK1138771A1 (en) | Antibodies against erbb3 and uses thereof | |
ZA200810311B (en) | Anti-NKG2A antibodies and uses thereof | |
ZA200900351B (en) | Prlr-specific antibody and uses thereof | |
IL205571A0 (en) | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin | |
IL236237A (en) | Tmem154 antibodies and their segments and uses | |
HK1203206A1 (en) | Antibody and use thereof | |
EP2193144A4 (fr) | Anticorps contre la flagelline et leurs utilisations | |
EP2379106A4 (fr) | Antigènes de chlamydias et leurs utilisations | |
EP2388320A4 (fr) | Anticorps anti-hs6st2 et son utilisation | |
GB0812277D0 (en) | Antibody and uses thereof | |
GB0707069D0 (en) | Methods and uses | |
ZA200905136B (en) | Anti-robo4 antibodies and uses therefor | |
GB0707609D0 (en) | Methods and uses | |
GB0722451D0 (en) | Methods and uses |